This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/mesh/concept/
n23http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/pubchem-substance/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/drugbank/
n22http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n6http://www.rxlist.com/cgi/generic/
n21http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
n11http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n27http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/wikipedia/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01623/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01623
rdf:type
n3:Drug
n3:description
A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. [PubChem]
n3:dosage
n19:271B5D64-363D-11E5-9242-09173F13E4C5 n19:271B5D65-363D-11E5-9242-09173F13E4C5 n19:271B5D66-363D-11E5-9242-09173F13E4C5 n19:271B5D67-363D-11E5-9242-09173F13E4C5 n19:271B5D68-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
10-20 hours
n3:indication
For the management of schizophrenia.
owl:sameAs
n21:DB01623 n22:DB01623
dcterms:title
Thiothixene
adms:identifier
n8:819430 n9:DB01623 n13:46505564 n14:PA451669 n15:941651 n17:0049-5710-66 n26:Thiothixene
n3:mechanismOfAction
Thiothixene acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
n3:packager
n23:271B5D5B-363D-11E5-9242-09173F13E4C5 n23:271B5D59-363D-11E5-9242-09173F13E4C5 n23:271B5D5A-363D-11E5-9242-09173F13E4C5 n23:271B5D53-363D-11E5-9242-09173F13E4C5 n23:271B5D54-363D-11E5-9242-09173F13E4C5 n23:271B5D51-363D-11E5-9242-09173F13E4C5 n23:271B5D52-363D-11E5-9242-09173F13E4C5 n23:271B5D57-363D-11E5-9242-09173F13E4C5 n23:271B5D58-363D-11E5-9242-09173F13E4C5 n23:271B5D55-363D-11E5-9242-09173F13E4C5 n23:271B5D56-363D-11E5-9242-09173F13E4C5 n23:271B5D4B-363D-11E5-9242-09173F13E4C5 n23:271B5D4C-363D-11E5-9242-09173F13E4C5 n23:271B5D4A-363D-11E5-9242-09173F13E4C5 n23:271B5D4F-363D-11E5-9242-09173F13E4C5 n23:271B5D50-363D-11E5-9242-09173F13E4C5 n23:271B5D4D-363D-11E5-9242-09173F13E4C5 n23:271B5D4E-363D-11E5-9242-09173F13E4C5
n3:synonym
(e)-thiothixene Navane Thiothixene Cis-thiothixene Thiothixine Tiotixene Tiotixenum Tiotixeno
n3:toxicity
Symptoms of overdose include central nervous system depression, coma, difficulty swallowing, dizziness, drowsiness, head tilted to the side, low blood pressure, muscle twitching, rigid muscles, salivation, tremors, walking disturbances, and weakness.
n3:foodInteraction
Avoid alcohol
n11:hasConcept
n12:M0021384
foaf:page
n6:thiothix.htm n16:thiothixene.html n27:nav1285.shtml
n3:IUPAC-Name
n4:271B5D6D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D73-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D72-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D6F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D70-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D71-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D6B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D69-363D-11E5-9242-09173F13E4C5 n4:271B5D6C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5D6A-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:N05AF04
n3:H-Bond-Acceptor-Count
n4:271B5D79-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D7A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D74-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D75-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D77-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D76-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D78-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
5591-45-7
n3:category
n3:containedIn
n10:271B5D63-363D-11E5-9242-09173F13E4C5 n10:271B5D61-363D-11E5-9242-09173F13E4C5 n10:271B5D62-363D-11E5-9242-09173F13E4C5 n10:271B5D5C-363D-11E5-9242-09173F13E4C5 n10:271B5D5F-363D-11E5-9242-09173F13E4C5 n10:271B5D60-363D-11E5-9242-09173F13E4C5 n10:271B5D5D-363D-11E5-9242-09173F13E4C5 n10:271B5D5E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5D7E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D80-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D81-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D7D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D7C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D7F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D6E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D7B-363D-11E5-9242-09173F13E4C5